| Immunogenicity and Safety of Live Attenuated Vaccine(MAV/06srtain) on Healthy Children and Immunocompromised Children |
|
Young Mo Sohn1, Chul Joo Yu1, Pyung Kil Kim1, Kir Young Kim1, Chong Young Park2, Mi Ran Kim2, Woo Kap Jeung2, Kyu Kye Hwang3, Gyu Jin Woo3, Song Yong Park3 |
1Department of Pediatrics, Yonsei University, College of Medicine, Seoul, Korea
1Department of Pediatrics, Yonsei University, College of Medicine, Seoul, Korea
2Department of Pediatrics, Hanlim University, College of Medicine, Chuncheon, Korea
3Mogam Biotechnology Research Institute, YongIn, Korea |
| 건강한 소아와 면역기능저하자에서 약독화 수두백신(MAV/06주)의 면역원성 및 안전성에 대한 연구 |
|
손영모1, 유철주1, 김병길1, 김길영1, 박종영2, 김미란2, 정우갑2, 황규계3, 우규진3, 박송용3 |
1연세대학교 의과대학 소아과학교실
1연세대학교 의과대학 소아과학교실
2한림대학교 의과대학 소아과학교실
3목암생명공학연구소 |
|
|
|
|
| Abstract |
Purpose
: To study the safety and immunogenicity of new live attenuated varicella vaccine (MAV/06strain) in normal healthy children and immunocompromized children in Korea.
Methods
: Blood samples for fluorescent antibody to membrane antigen(FAMA) assay were taken before the vaccination among seven hundred forth five healthy children and twenty two nine immunocompromised children. One hundred and seventy seven children and twenty two immunocompromized children(leukemia 6, solid tumor 10, nephrotic syndrome 6) were immunized with live attenuated varicella vaccine(Suduvax). Clinical response were observed after vaccination during the study period.
Results
: Among one hundred and sixty one healthy children who were able to follow up, mild local reactions were developed ; the pain and tenderness in 36 cases(22.4%), swalling and induration in 27 cases(16.8%), redness in 19 cases(11.8%) during first three days after vaccination. Fever developed in 4 cases(2.5%), headche in 4 cases(2.5%), loss of appetite in 3 cases(1.9%), rash with vesicles in 1 case as a geometric mean titre(GMT) was 173.7¡¾29.8, Among eighteen immunocompromised children(leukemia 2, solid tumor 10, nephrotic syndrome 6) who were able to follow up, 3 cases of pain and tenderness(16.7%), 3 cases of swalling and induration(16.7%), 3 case of redness(16.7%) at injection site and 1 case of fever, 1 case of generalized erythematous rash without vesicels were developed. Seroconversion rate of immunocompromised children was 100%(18/18) and GMT was 111.4¡¾19.2. All side reaction subsided spontaneously without any medical teratment.
Conclusions
: This live attenuated varicella varicella vaccine(MAV/06 strain) appear to be well tolerated and highly immunogenic in immunocompromised children as well as in normal healthy children. |
| Key Words:
Immunogenicity, live attenuated Varicella Virus Vaccine, Immuncompromised |
|
PDF Links
Download Citation
